Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction

Klaus-Werner von Pape; Gerhard Strupp; Tassilo Bonzel; Jürgen Bohner

doi:10.1055/s-0037-1615582

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(04): 889-891
DOI: 10.1055/s-0037-1615582

Letters to the Editor

Schattauer GmbH

Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction

Klaus-Werner von Pape

¹Institute for Laboratory Medicine

,

Gerhard Strupp

²Department of Internal Medicine I, Klinikum Fulda, Germany

,

Tassilo Bonzel

²Department of Internal Medicine I, Klinikum Fulda, Germany

,

Jürgen Bohner

¹Institute for Laboratory Medicine

› Author Affiliations

Abstract

Full Text

References

References
1 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.. Lancet 1988; 2: 349-60.
2 Eccles M, Freemantle N, Mason J.. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.. Br Med J 1998; 316: 1303-9.
3 Antithrombotic Trialists' Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.. Br Med J 2002; 324: 71-86.
4 Fitzgerald GA.. Parsing an enigma: the pharmacodynamics of aspirin resistance.. Lancet 2003; 361: 542-4.
5 Bohner J, von Pape K-W, Wiebersinsky W. et al. Serial assesment of platelet function following a single 300 mg dose of acetyl salicylic acid.. Ann Hematol 1997; 74 (Suppl. 02) A136.
6 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.. J Am Coll Cardiol 2003; 41: 961-5.
7 Patrono C.. Aspirin resistance: definition, mechanisms and clinical read-outs.. J Thromb Haemost 2003; 1: 1710-3.
8 Mason PJ, Freedman JE, Jacobs AK.. Aspirin resistance: current concepts.. Rev Cardiovasc Med 2004; 5: 156-63.
9 Grotemeyer K, Scharafinski H, Husstedt IW.. Two- year follow-up of aspirin responder and aspirin non re- sponder. A pilot study including 180 post-stroke patients.. Thromb Res 1993; 71: 397-403.
10 Bach R, Jung F, Kohsiek I. et al. Factors affecting the restenosis rate after PTCA.. Thromb Res 1994; 74: 55-67.
11 von Pape K-W, Aland E, Bohner J.. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample.. Thromb Res 2000; 98: 295-9.
12 Kundu SK, Heilmann EJ, Sio R. et al. Description of an in vitro platelet function analyzer--PFA-100.. Semin Thromb Haemost 1995; 21 (Suppl. 02) 106-12.
13 Mammen EF, Alshameeri RS, Comp PC.. Preliminary data from a field trial of the PFA-100 system.. Semin Thromb Haemost 1995; 21 (Suppl. 02) 113-21.
14 Pulcinelli FM, Pignatelli P, Celestini A. et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients.. J Am Coll Cardiol 2004; 43: 979-84.
15 Cerletti C, Dell'Elba G, Manarini S. et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.. Clin Pharmacokinet 2003; 42: 1059-70.
16 Weber AA, Przytulski B, Schanz A. et al. Towards a definition of aspirin resistance: a typological approach.. Platelets 2002; 13: 37-40.